TEVA, US8816242098

Zacks downgrades Teva stock to Strong Sell below yearly high

Published on 10/26/2026 at 15:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 4.15 billion, up 4.01 percent. Teva stock was USD 39.72 on October 26, 2026, up 0.79 percent from USD 39.41.

Zacks rating changes on October 20

Zacks Research downgraded Teva from Hold to Strong Sell in a note dated October 20, 2026.
Second-quarter revenue reached USD 4.15 billion, up 4.01 percent from the first quarter.
Teva stock was USD 39.72 on October 26, 2026, up 0.79 percent from the USD 39.41 prior close.
Teva is scheduled to report third-quarter results on November 3, 2026.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries Limited (ISIN US8816242098) was downgraded from Hold to Strong Sell by Zacks Research in a note issued on October 20, 2026, according to MarketBeat. Teva stock was trading at USD 39.72 on October 26, 2026 at 10:30 a.m. ET, up 0.79 percent from the prior close of USD 39.41.

Revenue rose between quarters

Teva's second-quarter revenue reached USD 4.15 billion in the quarter ended June 30, 2026, compared with USD 3.99 billion in the first quarter. That represents growth of 4.01 percent between the two reported periods, based on figures published by US News. The revenue progression gives the rating change a concrete operating backdrop, although the two quarters should not be treated as a full-year forecast.

Stock remains below its yearly high

The US quote stood 5.47 percent below its 52-week high of USD 42.02 and 109.05 percent above its 52-week low of USD 19.00 on October 26, 2026. Market capitalization was USD 46.3 billion, while reported volume stood at 1,028,284 shares at 10:30 a.m. ET. The current level therefore sits near the upper end of the annual range without setting a new high.

Valuation meets the next date

Teva's quoted price-to-earnings ratio was 66.23 on October 26, 2026, alongside the USD 46.3 billion market capitalization. The next scheduled corporate milestone is the third-quarter results report on November 3, 2026, listed by Nordnet. The timing leaves the upcoming report as the next dated test for revenue progress and the market's response to the Zacks downgrade.

What the figures say now

The combination of 4.01 percent quarter-over-quarter revenue growth and a share price 5.47 percent below its yearly high puts the focus on execution rather than a new price record. Teva trades on the NYSE under the ticker TEVA, and the latest quote was USD 39.72 on October 26, 2026 at 10:30 a.m. ET.